Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid

Acta Oncologica

Volumn 44, Issue 6, 2005, Pages 644-650

  Ullén, Anders ^a,c   Lennartsson, Lena ^a   Harmenberg, Ulrika ^a   Hjelm Eriksson, Marie ^a   Kalkner, Karl Mikael ^a   Lennernäs, Bo ^b   Nilsson, Sten ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; DOCETAXEL; ZOLEDRONIC ACID;

ARTICLE; CANCER CELL; CELL LINE; CONTROLLED STUDY; DRUG EFFECT; FLUOROMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; MENTAL CONCENTRATION; OSTEOLYSIS; PRIORITY JOURNAL; PROSTATE CANCER;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; CELL LINE, TUMOR; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; HUMANS; IMIDAZOLES; MALE; MITOSIS; PROSTATIC NEOPLASMS; TAXOIDS;

EID: 27144522528     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/02841860510029617     Document Type: Article

References (36)

1. Falkmer U, Jarhult J, Wersall P, Cavallin-Stahl E. A systematic overview of radiation therapy effects in skeletal metastases. Acta Oncol 2003;42:620-33.
2. Roland S. Calcium studies in ten cases of osteoblastic prostatic metastases. J Urol 1958;79:339-42.
3. Clarke NW, McClure J, George NJ. Morphometric evidence for bone resorption and replacement in prostate cancer. Br J Urol 1991;68:74-80.
4. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. A randomized placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94:1458-68.
5. Saad F. Zoledronic acid significantly reduces pathologic fractures in patients with advanced-stage prostate cancer metastatic to bone. Clin Prostate Cancer 2002;1:145-52.
6. Shipman CM, Croucher PI, Russell RG, Helfrich MH, Rogers MJ. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res 1998; 58:5294-7.
7. Coxon FP, Benford HL, Russell RG, Rogers MJ. Protein synthesis is required for caspase activation and induction of apoptosis by bisphosphonate drugs. Mol Pharmacol 1998;54:631-8.
8. Oades GM, Senaratne SG, Clarke IA, Kirby RS, Colston KW. Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway impairing Ras membrane localization in prostate cancer cells. J Urol 2003; 170:246-52.
9. Aparicio A, Gardner A, Tu Y, Savage A, Berenson J, Lichtenstein A. In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia 1998; 12:220-9.
10. Shipman CM, Rogers MJ, Apperley J, Graham R, Russell G, Croucher PI. Anti-tumour activity of bisphosphonates in human myeloma cells. Leuk Lymphoma 1998;32:129-38.
11. Shipman CM, Rogers MJ, Vanderkerken K, Van Camp B, Graham R, Russell G, Croucher PI. Bisphosphonates-mechanisms of action in multiple myeloma. Acta Oncol 2000;39:829-35.
12. Fromigue O, Lagneaux L, Body JJ. Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res 2000;15:2211-21.
13. Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 2000;82:1459-68.
14. Dumon JC, Journe F, Kheddoumi N, Lagneaux L, Body JJ. Cytostatic and apoptotic effects of bisphosphonates on prostate cancer cells. Eur Urol 2004;45:521-8; discussion 528-9.
15. Lee MV, Fong EM, Singer FR, Guenette RS. Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res 2001;61:2602-8.
16. Corey E, Brown LG, Quinn JE, Poot M, Roudier MP, Higano CS, Vessella RL. Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin Cancer Res 2003;9:295-306.
17. Jagdev SP, Coleman RE, Shipman CM, Rostami HA, Croucher PI. The bisphosphonate zoledronic acid induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer 2001;84:1126-34.
18. Witters LM, Crispino J, Fraterrigo T, Green J, Lipton A. Effect of the combination of docetaxel zoledronic acid and a COX-2 inhibitor on the growth of human breast cancer cell lines. Am J Clin Oncol 2003;26:S92-7.
19. Tassone P, Forciniti S, Galea E, Morrone G, Turco MC, Martinelli V, et al. Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines. Leukemia 2000;14:841-4.
20. Eisenberger MA, De Wit R, Berry W, et al. A multicenter phase III comparison of docetaxel (D)+prednisone (P) and mitoxantrone (MTZ)+P in patients with hormone refractory prostate cancer(HRPC), ASCO Abstract 4 Genitourinary cancer category prostate cancer subcategory 2004.
21. Larsson R, Kristensen J, Sandberg C, Nygren P. Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia using a fluorometric microculture cytotoxicity assay (FMCA). Int J Cancer 1992; 50:177-85.
22. Carlin BI, Andriole GL. The natural history skeletal complications and management of bone metastases in patients with prostate carcinoma. Cancer 2000;88:2989-94.
23. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004;96:879-82.
24. Rogers MJ, Watts DJ, Russell RG. Overview of bisphosphonates. Cancer 1997;80:1652-60.
25. Rodan GA. Mechanisms of action of bisphosphonates. Annu Rev Pharmacol Toxicol 1998;38:375-88.
26. Flanagan AM, Chambers TJ. Inhibition of bone resorption by bisphosphonates: interactions between bisphosphonates osteoclasts and bone. Calcif Tissue Int 1991;49:407-15.
27. Van der Pluijm G, Vloedgraven H, van Beek E, van der Wee-Pals L, Lowik C, Papapoulos S. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest 1996;98:698-705.
28. Boissier S, Magnetto S, Frappart L, Cuzin B, Ebetino FH, Delmas PD, Clezardin P. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res 1997; 57:3890-4.
29. Berenson JR, Rosen L, Vescio R, Lau HS, Woo M, Sioufi A, et al. Pharmacokinetics of pamidronate disodium in patients with cancer with normal or impaired renal function. J Clin Pharmacol 1997;37:285-90.
30. Body JJ, Gaich GA, Scheele WH, Kulkarni PM, Miller PD, Peretz A, et al. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002; 87:4528-35.
31. Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002;346:653-61.
32. Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, et al. Bisphosphonate action, alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 1991;88:2095-105.
33. O'Rourke N, McCloskey E, Houghton F, Huss H, Kanis JA. Double-blind placebo-controlled dose-response trial of oral clodronate in patients with bone metastases. J Clin Oncol 1995;13:929-34.
34. Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 1996;335:1785-91.
35. Diel IJ, Solomayer EF, Costa SD, Gollan C, Goerner R, Wallwiener D, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998;339:57-63.
36. Vordos D, Paule B, Vacherot F, Allory Y, Salomon L, Hoznek AY, et al. Docetaxel and zoledronic acid in patients with metastatic hormone-refractory prostate cancer. BJU Int 2004;94:524-7.